tislelizumab + BAT1706

**Tislelizumab + BAT1706** is a combination drug comprised of tislelizumab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), and BAT1706, a humanized monoclonal antibody biosimilar to bevacizumab targeting vascular endothelial growth factor A (VEGF-A). Tislelizumab, developed primarily for immunotherapy, blocks PD-1, thus enhancing anti-tumor immune responses. BAT1706 is designed to inhibit VEGF-mediated angiogenesis and tumor vascularization, thereby limiting tumor growth. The combination is being evaluated in clinical trials, notably in hepatocellular carcinoma and other advanced cancers, aiming to leverage synergistic effects of immune checkpoint inhibition and anti-angiogenic therapy[3][5].

Brand names

Avzivi

Other names

bevacizumab biosimilar